The impact of SGLT2-inhibitor on SLE outcomes SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors. https://t.co/hyyMVQg3xV https://t.co/fLxh0vlTze

Are Rheumatologists doing Enough for Cervical Cancer? Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients. https://t.co/VFobM0T3u7 https://t.co/L45N3tsTdN

Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/91PtvQfoIr https://t.co/ZjYCVP5lqG

Long term F/U of early RA, T2T RCTs (n 1616) finds excess mortality > 10yrs for BeST (SMR 1.32) & IMPROVED (SMR 1.33) RCTs; highest in ACPA+ smokers (SMR 2.80 & 2.14); Cancer main cause. SMR incr 34% & 13% for ea 1 pt incr in DAS https://t.co/2DdHMGIlOk https://t.co/7bnCOzB8vd

Infections During Treatment of GPA with Rituximab Dr. Richard Conway (Dublin, Ireland) discusses abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/eKi3KExEnk https://t.co/b9G9w5e9tc

Watch and Weigh In: Upadacitinib for Pain: Is That Real? Dr. David Liew reports on abstract 0429 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AbD9UpXQfY https://t.co/iRgUnNInuD

Computer Vision: Is It Ready for RA Assessment? Dr. David Liew reports on abstract 0402 and 1293 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/4rQDjFXjH2 https://t.co/8FM40kh3bw

Hemophagocytic Lymphohistiocytosis in Still's Disease Dr. Bella Mehta discusses abstract 1143 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/bFeGK6MTcc https://t.co/cxJg6rQ7gm

Watch: Deep Neural Networks and Radiographic Progression in AxSpA Dr. Antoni Chan discusses abstracts 1389 and 1398 presented at the 2023 ACR Convergence in San Diego, CA. https://t.co/F9hpNvmvVc https://t.co/xR0uW1CkUw

The impact of SGLT2-inhibitor on SLE outcomes SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors. https://t.co/BjjerQhsrR https://t.co/vpzSaAIOjU

Are Rheumatologists doing Enough for Cervical Cancer? Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients. https://t.co/FKaLSiBHV6 https://t.co/zR46JU5mlR

Combined 4 tofacitinib RCTs (4404 pts) found baseline probable major depression or anxiety disorder in 44.5%, 39.8%, 45.4%, 39.1% on TOFA 5 BID, TOFA 10 BID, adalimumab, & placebo. Effective RA Rx w/ Tofa or ADA lead to improved depression and anxiety https://t.co/y6UoFXANo7 https://t.co/aV5uV9qWbz